Hepatocellular Carcinoma
Cross-source consensus on Hepatocellular Carcinoma from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Risks & contraindications
Comparisons
Other
Highlighted claims
- Hepatocellular carcinoma is the sixth most common cancer worldwide and the third leading cause of cancer-related death. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- Curative treatments for very early or early-stage HCC include surgical resection and local ablative therapies when liver function is preserved. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- Up to 70% of patients experience HCC recurrence within five years after initial curative treatment. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- Late HCC recurrence beyond two years reflects new tumor development in the remaining liver rather than residual microscopic metastases. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- Early and late HCC recurrence are biologically distinct and require different surveillance approaches. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol